CD19-targeted t cells for hematologic malignancies clinical experience to date Journal Article

Authors: Davila, M. L.; Sauter, C.; Brentjens, R.
Article Title: CD19-targeted t cells for hematologic malignancies clinical experience to date
Abstract: Recently, immunotherapy for cancer has begun to garner traction with encouraging results in a number ofmalignancies. Included within this arena has been the genetic engineering of autologous T cells with chimeric antigen receptors (CARs) against tumor target. The majority of this experience has included the use of CAR T cells directed against CD19 for B-cell hematologic malignancies. The most striking efficacy to date with CAR T cells directed against CD19 has been in relapsed and refractory B-cell acute lymphoblastic leukemia, with the overwhelming majority of patients experiencing complete remissions. In addition, singlecenter and largely early-phase studies have demonstrated responses in patients with varying histologic findings of relapsed and refractory B-cell non-Hodgkin lymphoma. The favorable response rates seen with this technology have been tempered by the high risk of toxicity, particularly in the form of cytokine-release syndrome and neurotoxicity. Agents such as tocilizumab and corticosteroids have been used to treat these toxicities. The current state of the science includes strategies to circumvent and treat toxicity, manufacturing, and study of later-generation CAR constructs with the intention of improving efficacy and development of CARs against other tumor targets for both hematologic and solid tumor malignancies. The observation of an early efficacy ensures further integration and development of this modality into future immunotherapeutic strategies for various cancers. © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: cancer chemotherapy; event free survival; review; disease free survival; follow up; t lymphocyte; cancer immunotherapy; acute lymphoblastic leukemia; hematologic malignancy; dna modification; immunotherapy; chimeric antigen receptor; adoptive transfer; large cell lymphoma; chronic lymphatic leukemia; personal experience; cd19 antigen; phase 2 clinical trial (topic); phase 1 clinical trial (topic); cytokine release syndrome; intention to treat analysis; cancer; human; priority journal
Journal Title: The Cancer Journal
Volume: 21
Issue: 6
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2015-11-01
Start Page: 470
End Page: 474
Language: English
PROVIDER: scopus
PMCID: PMC4656120
PUBMED: 26588678
DOI: 10.1097/PPO.0000000000000153
Notes: Review -- Export Date: 7 January 2016 -- 470 -- Source: Scopus
Citation Impact
MSK Authors
  1. Renier J Brentjens
    274 Brentjens
  2. Craig Steven Sauter
    286 Sauter